Price
No data yet.
Social Signal Score
Revenue
$186.2K+269.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Todd Michael Shapiro
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 104
- Beta
- 0.96
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.20
Financials
Revenue
$186.2K+269.5%Net Income
$-1.50M-1953.7%EBITDA
$-1.34MFree Cash Flow
$-889.4K-4319.4%EPS (diluted)
$-0.00-101.5%Shares Outstanding (diluted)
551.45M+123521.4%Operating Expenses
$1.61MCash & Debt
$8.13MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $4.20M | $-6.10M | $-0.01 |
| 2025 | $4.94M | $-4.04M | $-0.01 |
| 2024 | $4.75M | $-7.63M | $-0.02 |
| 2023 | $3.95M | $-5.40M | $-0.01 |
| 2022 | $111.0K | $-1.64M | $-0.00 |
| 2021 | $111.0K | $-325.2K | $-0.00 |
| 2020 | $0.00 | $-325.2K | $-0.00 |
| 2019 | $10.8K | $-180.0K | $-0.00 |
| 2018 | $40.8K | $-309.4K | $-0.00 |
| 2017 | $187.5K | $145.3K | $0.17 |
| 2016 | $378.4K | $510.9K | $2.42 |
| 2015 | $727.9K | $258.5K | $0.85 |
| 2014 | $209.4K | $348.1K | $1.57 |
| 2013 | $799.4K | $-3.04M | $-15.35 |
Valuation
TRUFFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (9)
- Newsnewsfilecorp.com·3d ago·Negative
…g and supporting more than 80 studies worldwide. Toronto, Ontario--(Newsfile Corp. - November 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
View source ↗ - Newsnewsfilecorp.com·37d ago·Neutral
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial. Filament will offer regulatory support and update on the program's progress towards regulatory approv
View source ↗ - Newsnewsfilecorp.com·39d ago·Neutral
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health. Toronto, Ontario--(Newsfile Corp. - October 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
View source ↗ - Newsnewsfilecorp.com·45d ago·Negative
…mine use, a condition with no approved medication. Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
View source ↗ - Newsnewsfilecorp.com·61d ago·Negative
…g and supplying more than 80 studies worldwide. Toronto, Ontario--(Newsfile Corp. - September 22, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
View source ↗ - Newsnewsfilecorp.com·69d ago·Negative
…gs", being held later today, September 14, 2026 Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that Sarit Hashkes, President of its wholly owned subsidiary Filament Health Corp. ("Filament"), will deliver oral comments at the United States Food and Drug Administration…
View source ↗ - Newsnewsfilecorp.com·83d ago·Neutral
…n Life Sciences Reports First Quarter 2027 Results Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its financial and operational results for the three months ended June 30, 2026 ("Q1 2027"), capping a transitional quarter which culminated in the acquisition of Filament Heal…
View source ↗ - Newsnewsfilecorp.com·95d ago·Neutral
…ces Announces Appointment of Samiuddin Khaja as CFO Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce the appointment of Samiuddin Khaja as Chief Financial Officer ("CFO") effective immediately. The appointment comes as Rhelion continues its evolution into a focused, researc…
View source ↗ - Newsnewsfilecorp.com·100d ago·Neutral
…the treatment of depression in Parkinson's disease. Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector.
View source ↗
Earnings
Mon, Nov 30(in 7 days)
Estimates and results for TRUFF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in TRUFF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
